Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tanya S. Rosenberg"'
Autor:
Peter M. Voorhees, Anita D'Souza, Katja Weisel, David Duane Hurd, Raphael Teipel, Alfred Chung, Cesar Rodriguez, Sascha A. Tuchman, Neha Korde, Hana Safah, Orlando F. Bueno, Neil Pumford, Tanya S Rosenberg, Rajvineeth Kumar Pothacamury, Jeremy A. Ross, Akshanth R. Polepally, Shane Lee, Ziyi Jin, Chetasi Talati, Ravi Vij, Shaji K Kumar
Publikováno v:
Blood. 140:4401-4404
Autor:
Abdullah A. Masud, Tara Cochrane, Stan Fort, Arnon P. Kater, Mary Ann Anderson, Tanya S. Rosenberg, Francesco Forconi, Simon Sharmokh, Matthew S. Davids, Brian Leber, Nikitin Ea, Fatih Demirkan, Yair Herishanu
e20011 Background: Neutropenia is a common hematologic Grade (Gr) 3+ adverse event (AE) recorded in patients with chronic lymphocytic leukemia (CLL) receiving venetoclax (VEN). In this analysis, we evaluated fixed duration VEN monotherapy given to pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6130314595e0140457401c1fb010aa43
https://avesis.deu.edu.tr/publication/details/bf381d5c-041f-40e2-bffd-8f05cc866edc/oai
https://avesis.deu.edu.tr/publication/details/bf381d5c-041f-40e2-bffd-8f05cc866edc/oai
Autor:
Aimee Cyr, John G. Gribben, German Pena, Simon Sharmokh, William G. Wierda, Matthew S. Davids, Cynthia Bartkus, Anthony R. Mato, Jeff P. Sharman, Tanya S. Rosenberg, John F. Seymour, Michelle Boyer
Publikováno v:
Blood. 136:37-38
Introduction: Venetoclax (Ven) has changed the chronic lymphocytic leukemia (CLL) treatment landscape with the ability to produce deep responses that result in improved long-term outcomes with well-tolerated fixed-duration regimens. Due to its potent
Autor:
Tanya S. Rosenberg, Stan Fort, Simon Sharmokh, Mary Ann Anderson, Fatih Demirkan, Arnon P. Kater, Yair Herishanu, Nikitin Ea, Francesco Forconi, Tara Cochrane, Matthew S. Davids, Abdullah A. Masud, Brian Leber
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S220
Background Neutropenia is a common hematologic Grade (Gr) 3+ adverse event (AE) recorded in patients with chronic lymphocytic leukemia (CLL) receiving venetoclax (VEN). In this analysis, we evaluated fixed duration VEN monotherapy given to patients w